{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:39:43Z","timestamp":1777718383392,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Tavaborole is a topical antifungal agent approved by the US Food and Drug Administration for the treatment of toenail onychomycosis. The effects of tavaborole on gestation, parturition (delivery, labor), offspring development, and survival during the perinatal and postnatal periods were assessed in mated female rats. Females (F0 generation) were administered single daily oral (gavage) doses of 15, 60, or 100 mg\/kg\/d from gestation day 6 through lactation day 20. The females were allowed to deliver naturally and rear their offspring until lactation day 21, at which time the F0 females were euthanized. One male and female from each litter were selected (F1 generation) and retained for assessments, including growth, neurobehavior, fertility, and their ability to produce an F2 generation. Reproductive and offspring parameters were determined for the F1 and F2 generations, as applicable. F1 females and F2 pups were euthanized on postnatal day 7. In the F0 females, decreased activity was observed in the 100 mg\/kg\/d dose group. Excess salivation was observed in the 60 and 100 mg\/kg\/d dose groups (slight to moderate), however, this finding was not considered adverse. There were no tavaborole-related effects on the growth, viability, development, neurobehavioral assessments, or reproductive performance of the F1 generation. Survivability and mean body weight of the F2 pups were unaffected. The no observed adverse effect level (NOAEL) for maternal toxicity (F0 generation) was 60 mg\/kg\/d, based on the decreased activity observed in the 100 mg\/kg\/d dose group. The NOAEL for the offspring effects was \u2265100 mg\/kg\/d, based on the lack of test article-related changes.<\/jats:p>","DOI":"10.1177\/1091581816641938","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T21:29:14Z","timestamp":1462224554000},"page":"543-557","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Tavaborole, a Novel Boron-Containing Small Molecule Pharmaceutical Agent for Topical Treatment of Onychomycosis"],"prefix":"10.1177","volume":"35","author":[{"given":"Vic","family":"Ciaravino","sequence":"first","affiliation":[{"name":"Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Coronado","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Lanphear","sequence":"additional","affiliation":[{"name":"MPI Research, Mattawan, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Hoberman","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Horsham, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Chanda","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1159\/000017990"},{"key":"bibr2-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.157"},{"key":"bibr3-1091581816641938","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-12-571"},{"key":"bibr4-1091581816641938","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-87-12-565"},{"key":"bibr5-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70484-0"},{"key":"bibr6-1091581816641938","unstructured":"Lamisil (terbinafine hydrochloride) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013."},{"key":"bibr7-1091581816641938","unstructured":"Sporanox (itraconazole) capsules [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2012."},{"key":"bibr8-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603724"},{"key":"bibr9-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142189"},{"key":"bibr10-1091581816641938","unstructured":"Kerydin\u00ae (tavaborole) topical solution, 5% [package insert]. Palo Alto, CA: Anacor Pharmaceuticals, Inc; 2014."},{"key":"bibr11-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1177\/1091581814545245"},{"key":"bibr12-1091581816641938","author":"Ciaravino V","journal-title":"Int J Toxicol"},{"key":"bibr13-1091581816641938","unstructured":"Prenatal and postnatal developmental toxicity and maternal function study of SCH 900340 (AN2690) administered orally by gavage in rats. Testing Facility: Charles River Laboratories, Preclinical Services Pennsylvania (PCS-PA), Horsham, PA. Study No. BEA00521. Sponsor: Schering-Plough Research Institute (SPRI), Lafayette, NJ. November 6, 2008."},{"key":"bibr14-1091581816641938","unstructured":"ICH Harmonised Tripartite Guideline. Detection of toxicity to reproduction for medicinal products & toxicity to male fertility S5(R2). 2005."},{"key":"bibr15-1091581816641938","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"Institute of Laboratory Animal Resources Commission on Life Sciences and the National Research Council","year":"1996"},{"key":"bibr16-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1007\/BF02308461"},{"key":"bibr17-1091581816641938","first-page":"370","volume-title":"Biometry: The Principles and Practice of Statistics in Biological Research","author":"Sokal RR","year":"1969"},{"key":"bibr18-1091581816641938","first-page":"258","volume-title":"Statistical Methods","author":"Snedecor GW","year":"1967","edition":"6"},{"key":"bibr19-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1955.10501294"},{"key":"bibr20-1091581816641938","first-page":"388","volume-title":"Biometry: The Principles and Practice of Statistics in Biological Research","author":"Sokal RR","year":"1969"},{"key":"bibr21-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1964.10490181"},{"key":"bibr22-1091581816641938","first-page":"96","volume-title":"Nonparametric Statistics for the Behavioral Sciences","author":"Siegel S","year":"1956"},{"key":"bibr23-1091581816641938","volume-title":"Repeated-Measures Analysis. Ch 8. SAS\u00ae for Linear Models","author":"Littell RC","year":"2002","edition":"4"},{"key":"bibr24-1091581816641938","unstructured":"Jublia (eficonazole) topical solution, 10% [package insert], Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807; 2014."},{"issue":"4","key":"bibr25-1091581816641938","first-page":"299","volume":"1","author":"Elewski B","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"bibr26-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"bibr27-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701243418"},{"key":"bibr28-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.415"},{"key":"bibr29-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00027-5"},{"key":"bibr30-1091581816641938","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00109.x"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581816641938","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1091581816641938","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581816641938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:25:00Z","timestamp":1777458300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581816641938"}},"subtitle":["II. Prenatal and Postnatal Developmental Toxicity and Maternal Function Study"],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1177\/1091581816641938"],"URL":"https:\/\/doi.org\/10.1177\/1091581816641938","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}